Xiande Liu, PHD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Genitourinary Med Onc - Rsch, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2005 | Chinese Academy of Sciences, Shanghai, CN, Ph.D. in Biological Sciences |
| 1997 | Jiangsu Normal University, Jiangsu, CN, BS in Biological Sciences |
| 2022 | UT MD Anderson Cancer Center School of Health Professions, US, Radiation Therapy |
Postgraduate Training
| 2005-2011 | Research Fellowship, Postdoctoral Fellowship, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2022 | Radiation Therapist |
Experience & Service
Faculty Academic Appointments
Instructor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2021
Instructor, Department of Medicine Baylor College of Medicine, Houston, TX, 2011 - 2012
Postdoctoral Associate, Department of Medicine Baylor College of Medicine, Houston, TX, 2005 - 2011
Lab Manager, Department of Biology Jiangsu Normal University, Jiangsu, 1997 - 2000
Extramural Institutional Committee Activities
Faculty Senator, UT MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2016 - 2018
Honors & Awards
| 2023 | Keystone Symposia Early Career Investigator Travel Award, Keystone Symposia |
| 2022 | Patricia Mack Blue Scholarship, MDACC School of Health Professions |
| 2022 | Summa Cum Laude Award (GPA 4.0), MDACC School of Health Professions |
| 2019 | AACR Scholar in Training Award, AACR |
| 2015 | ASCO Merit Award, ASCO |
| 2014 | ESMO Travel Grant, ESMO |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2020. PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma. Conference. PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma. Houston, TX, US.
National Presentations
- 2025. NPRL2 loss silences STING signaling from genomic instability and confers immunotherapy resistance. NPRL2 loss silences STING signaling from genomic instability and confers immunotherapy resistance. Boston, Massachusetts, US.
- 2023. SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma. Conference. SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma. Orlando, Florida, US.
- 2019. PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma. Conference. PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma. National Harbor, MD, US.
- 2019. PBRM1 loss reduced IFNg-STAT1 activity and promotes resistance to immunotherapy in renal cell carcinoma. Conference. PBRM1 loss reduced IFNg-STAT1 activity and promotes resistance to immunotherapy in renal cell carcinoma, GA, US.
- 2015. Sunitinib upregulates IFN-STAT1 signaling to modulate the tumor immune microenvironment in renal cell carcinoma. Conference. Sunitinib upregulates IFN-STAT1 signaling to modulate the tumor immune microenvironment in renal cell carcinoma. New York, US.
- 2015. Angiogenic treatment both positively and negatively regulate the tumor immune microenvironment in metastatic renal cell carcinoma. Conference. Angiogenic treatment both positively and negatively regulate the tumor immune microenvironment in metastatic renal cell carcinoma. Orlando, FL, US.
- 2015. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Conference. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Orlando, FL, US.
- 2014. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Conference. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Austin, TX, US.
- 2014. Identification of molecular drivers of human hemangioblastoma. Conference. Identification of molecular drivers of human hemangioblastoma. San Diego, CA, US.
- 2014. The mechanism of anti-VEGF therapy reisstance in renal cell carcinoma. Conference. The mechanism of anti-VEGF therapy reisstance in renal cell carcinoma. San Diego, CA, US.
- 2014. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. Conference. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. San Diego, CA, US.
- 2013. Identification of a small molecular compound that stabilizes VHL and decreases HIF2a. Conference. Baylor College of Medicine. San Diego, CA, US.
- 2013. The Role of FGF Signaling in VEGF-Pathway Targeted Therapy Resistance: Data From Patients and Model Systems. Conference. MD Anderson Cancer Center. San Diego, CA, US.
- 2012. Autophagy deficiency in myeloid cells results in spontaneous lung inflammation. Conference. Autophagy deficiency in myeloid cells results in spontaneous lung inflammation. San Francisco, CA, US.
- 2011. ALIS Formation Is a Cytosolic Unfolded Protein Response to Inflammation and Endoplasmic Reticulum Stress. Conference. ALIS Formation Is a Cytosolic Unfolded Protein Response to Inflammation and Endoplasmic Reticulum Stress. Denver, CO, US.
- 2010. BCG Infection Induces p62-Dependent Autophagy-Independent Formation of Dendritic Cell Aggresome-Like Structures. Conference. BCG Infection Induces p62-Dependent Autophagy-Independent Formation of Dendritic Cell Aggresome-Like Structures. New Orleans, LA, US.
- 2010. Harnessing of TLR-Mediated Autophagy to Eliminate Mycobacterium Tuberculosis From Macrophages. Conference. Harnessing of TLR-Mediated Autophagy to Eliminate Mycobacterium Tuberculosis From Macrophages. New Orleans, LA, US.
- 2009. Identification of a FMN Module Residue Critical for Activity of Inducible Nitrite Oxide Synthase. Conference. Identification of a FMN Module Residue Critical for Activity of Inducible Nitrite Oxide Synthase. San Diego, CA, US.
- 2007. Autophagy is regulated by TRIF-dependent Toll-like receptor 4 signaling pathway and participates in innate immunity against Mycobacterium tuberculosis. Conference. Autophagy is regulated by TRIF-dependent Toll-like receptor 4 signaling pathway and participates in innate immunity against Mycobacterium tuberculosis. San Francisco, CA, US.
- 2007. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Conference. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Monterey, CA, US.
International Presentations
- 2026. Spatial single-cell transcriptomics reveal targetable macrophage subsets associated with antiangiogenic therapy resistance in ccRCC. Conference. AACR Special Conference in Cancer Research: Innovations in Kidney. Philadelphia, US.
- 2025. NPRL2 loss silences STING signaling from genomic instability and promotes a CD8lowM2high microenvironment. Conference. NPRL2 loss silences STING signaling from genomic instability and promotes a CD8lowM2high microenvironment. Denver, US.
- 2024. VHL inactivation and tyrosine kinase inhibitors prevent PD-L1 degradation. VHL inactivation and tyrosine kinase inhibitors prevent PD-L1 degradation. Milan, US.
- 2024. VHL inactivation and tyrosine kinase inhibitors prevent PD-L1 degradation. VHL inactivation and tyrosine kinase inhibitors prevent PD-L1 degradation. Milan, IT.
- 2024. The upregulated IDO1 expression in macrophages correlates with sunitinib resistance in renal cell carcinoma. The upregulated IDO1 expression in macrophages correlates with sunitinib resistance in renal cell carcinoma. Killarney, IE.
- 2023. SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma. Conference. SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma. Vancouver, CA.
- 2019. PBRM1 loss reduces IFN-STAT1 activity and promotes resistance to immunotherapy in renal cell carcinoma. Conference. PBRM1 loss reduces IFN-STAT1 activity and promotes resistance to immunotherapy in renal cell carcinoma. Paris, FR.
- 2016. Macroautophagy and chaperone-mediated autophagy degrade immune checkpoint ligand PD-L1. Conference. Macroautophagy and chaperone-mediated autophagy degrade immune checkpoint ligand PD-L1. Whistler, CA.
- 2014. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. Conference. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. Barcelona, ES.
- 2014. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. Conference. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. Madrid, ES.
- 2014. Induced CD4 positive T-lymphocyte infiltration predicts poor survival in metastatic renal carcinoma patients treated with antiangiogenic therapy. Conference. Induced CD4 positive T-lymphocyte infiltration predicts poor survival in metastatic renal carcinoma patients treated with antiangiogenic therapy. Amsterdam, NL.
- 2011. p62 mediates a novel cytosolic response to unfolded proteins linking inflammation, ER Stress and Metabolic Syndrome. Conference. p62 mediates a novel cytosolic response to unfolded proteins linking inflammation, ER Stress and Metabolic Syndrome. Whistler, CA.
- 2004. NaCI-induced phosphorylation of light harvesting chlorophyll a/b proteins in thylakoid membranes from the halotolerant green alga, Dunaliella salina. Conference. Montréal, CA.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Targeting PRMT3-IGF2BP1 Axis-Mediated Epitranscriptomic Reprogramming as a Novel Therapeutic Strategy to Overcome Immunotherapy Resistance in ccRCC |
| Funding Source: | DOD KCRP-IDA |
| Role: | Co-PI |
| ID: | KC240193P1 |
| Date: | 2025 - 2029 |
| Title: | Functional and Clonal Characterization of the Extinction of HIF Signaling in VHL-Driven Renal Cancers |
| Funding Source: | DOD-PRMRP-IIRA |
| Role: | Co-I |
| ID: | PR240492 |
| Date: | 2024 - 2028 |
| Title: | Kidney Cancer Clinical Trials Consortium |
| Funding Source: | DOD |
| Role: | Co-I |
| ID: | KC230296 |
| Date: | 2023 - 2025 |
| Title: | SETD2 Loss Promotes cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma |
| Funding Source: | IRG |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Targeting the DNA Damage Repair Network to Promote an Innate Immune Response in ccRCC |
| Funding Source: | DOD |
| Role: | Co-I |
| ID: | W81XWH-21-1-0930 |
| Date: | 2019 - 2021 |
| Title: | S-phase DNA damage response links genomic instability mechanisms to anti-tumor immunity in renal cell carcinoma |
| Funding Source: | Kidney Cancer Association |
| Role: | Co-I |
| ID: | 1365766 |
| Date: | 2019 - 2021 |
| Title: | S-Phase DNA Damage Response Links Genomic Instability Mechanisms to Anti-Tumor Immunity in Kidney Cancer |
| Funding Source: | Kidney Cancer Association |
| Role: | Co-I |
| ID: | FP00008917 |
| Date: | 2017 - 2020 |
| Title: | Prognostic and Predictive Markers of Immunogenicity in Renal Cell Carcinoma |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-17-1-0307 |
| Date: | 2017 - 2022 |
| Title: | Biology and Exploitation of Molecular Drivers of Renal Cell Cancer Malignant Progression Translational Biology & Biostatistics Core (Jonasch) |
| Funding Source: | NIH/NCI (Stanford University Primary) |
| Role: | Co-I |
| ID: | P01 CA200527 |
| Date: | 2017 - 2020 |
| Title: | Immunological Impact of Axitinib on Avelumab Efficacy in Immune Competent RCC Animal Models |
| Funding Source: | Pfizer |
| Role: | Co-I |
| ID: | WI214302 |
| Date: | 2016 - 2019 |
| Title: | Preclinical Cabozantinib |
| Funding Source: | Exelixis |
| Role: | Co-I |
| ID: | EXEL#210016 |
| Date: | 2016 - 2019 |
| Title: | Preclinical Testing of a Novel Therapy Targeting AXL in Advanced Kidney Cancer |
| Funding Source: | NIH/NCI (Stanford University) |
| Role: | Co-I |
| ID: | R01 CA198291 |
| Date: | 2015 - 2018 |
| Title: | Mechanistic Studies of Cancer Cell Adaptive Response to P13K/AKT Inhibition |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA190370 |
| Date: | 2014 - 2016 |
| Title: | The Role of Autophagy in Renal Carcinogenesis |
| Funding Source: | MDACC Institutional Research Grant |
| Role: | Co-I |
| Date: | 2013 - 2014 |
| Title: | Kidney Cancer Research Program Pilot Project |
| Funding Source: | MDACC-Kidney MRP |
| Role: | Co-PI |
| Title: | Spatially mapping and targeting the tumor microenvironment in early-stage renal cell carcinoma |
| Funding Source: | VHLA Research Grant |
| Role: | Co-PI |
| Title: | VHL loss is associated with upregulated glycolysis and reduced antitumor immune response early stage ccRCC |
| Funding Source: | VHLA Research Grant |
| Role: | Co-PI |
| Title: | THOR-707 improves immunogenicity and response to immune checkpoint blockade in PBRM1 mutated RCC tumors |
| Funding Source: | Synthorx Preclinical Grant |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Liu, X, Zhang, YT, McGrail, DJ, Zhang, X, Lam, TA, Hoang, A, Hasanov, E, Manyam, GC, Peterson, CB, Zhu, H, Kumar, SV, Akbani, R, Pilie, PG, Tannir, NM, Peng, G, Jonasch, E. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clinical Cancer Research 29(19):4002-4015, 2023. e-Pub 2023. PMID: 37527013.
- Mathó, C, Fernández, MC, Bonanata, J, Liu, X, Martin, A, Vieites, A, Sansó, G, Barontini, M, Jonasch, E, Coitiño, EL, Pennisi, PA. VHL-P138R and VHL-L163R Novel Variants. Frontiers in Endocrinology 13, 2022. e-Pub 2022. PMID: 35388293.
- Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33806963.
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020. e-Pub 2020. PMID: 32358509.
- Cowman S, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher KM, Maughan BL, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1α is an independent prognostic indicator in kidney cancer. Clin Cancer Res, 2020. e-Pub 2020. PMID: 32586940.
- Gurumurthy CB, O'Brien AR, Quadros RM, Adams J, Alcaide P, Ayabe S, Ballard J, Batra SK, Beauchamp MC, Becker KA, Bernas G, Brough D, Carrillo-Salinas F, Chan W, Chen H, Dawson R, DeMambro V, D'Hont J, Dibb KM, Eudy JD, Gan L, Gao J, Gonzales A, Guntur AR, Guo H, Harms DW, Harrington A, Hentges KE, Humphreys N, Imai S, Ishii H, Iwama M, Jonasch E, Karolak M, Keavney B, Khin NC, Konno M, Kotani Y, Kunihiro Y, Lakshmanan I, Larochelle C, Lawrence CB, Li L, Lindner V, Liu XD, Lopez-Castejon G, Loudon A, Lowe J, Jerome-Majewska LA, Matsusaka T, Miura H, Miyasaka Y, Morpurgo B, Motyl K, Nabeshima YI, Nakade K, Nakashiba T, Nakashima K, Obata Y, Ogiwara S, Ouellet M, Oxburgh L, Piltz S, Pinz I, Ponnusamy MP, Ray D, Redder RJ, Rosen CJ, Ross N, Ruhe MT, Ryzhova L, Salvador AM, Alam SS, Sedlacek R, Sharma K, Smith C, Staes K, Starrs L, Sugiyama F, Takahashi S, Tanaka T, Trafford AW, Uno Y, Vanhoutte L, Vanrockeghem F, Willis BJ, Wright CS, Yamauchi Y, Yi X, Yoshimi K, Zhang X, Zhang Y, Ohtsuka M, Das S, Garry DJ, Hochepied T, Thomas P, Parker-Thornburg J, Adamson AD, Yoshiki A, Schmouth JF, Golovko A, Thompson WR, Lloyd KCK, Wood JA, Cowan M, Mashimo T, Mizuno S, Zhu H, Kasparek P, Liaw L, Miano JM, Burgio G. Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation. Genome Biol 20(1):171, 2019. e-Pub 2019. PMID: 31446895.
- Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361(6399):290-295, 2018. e-Pub 2018. PMID: 30026228.
- Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res 77(19):5313-5326, 2017. e-Pub 2017. PMID: 28807937.
- German P, Bai S, Liu XD, Sun M, Zhou L, Kalra S, Zhang X, Minelli R, Scott KL, Mills GB, Jonasch E, Ding Z. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function. Oncogene 35(38):4973-80, 2016. e-Pub 2016. PMID: 26973240.
- Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-97, 2016. e-Pub 2016. PMID: 26364599.
- Xu G, Jiang Y, Xiao Y, Liu XD, Yue F, Li W, Li X, He Y, Jiang X, Huang H, Chen Q, Jonasch E, Liu L. Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. Oncotarget 7(5):6255-65, 2016. e-Pub 2016. PMID: 26701856.
- Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
- Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene 34(19):2450-60, 2015. e-Pub 2015. PMID: 24998849.
- Liu, X, Zhu, H, DePavia, A, Jonasch, E. Dysregulation of HIF2α and autophagy in renal cell carcinoma. Molecular and Cellular Oncology 2(2), 2015. e-Pub 2015. PMID: 27308417.
- Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv Y, Fan X, Sang M, Liu XD, Liu W. The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression. Med Oncol 32(1):428, 2015. e-Pub 2015. PMID: 25502084.
- Ho TH, Liu XD, Huang Y, Warneke CL, Johnson MM, Hoang A, Tamboli P, Wang F, Jonasch E. The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer 15:304, 2015. e-Pub 2015. PMID: 25900027.
- Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res, 2015. e-Pub 2015. PMID: 26014097.
- Ding, Z, German, P, Bai, S, Reddy, AS, Liu, X, Sun, M, Zhou, L, Chen, X, Zhao, X, Wu, C, Zhang, S, Mills, GB, Jonasch, E. Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein. Cancer Research 74(11):3127-3136, 2014. e-Pub 2014. PMID: 24755468.
- Ding Z, German P, Bai S, Reddy AS, Liu XD, Sun M, Zhou L, Chen X, Zhao X, Wu C, Zhang S, Mills GB, Jonasch E. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Research 74:3127-36, 2014. e-Pub 2014.
- Chen W, Ayala-Orozco C, Biswal NC, Perez-Torres C, Bartels M, Bardhan R, Stinnet G, Liu XD, Ji B, Deorukhkar A, Brown LV, Guha S, Pautler RG, Krishnan S, Halas NJ, Joshi A. Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Nanomedicine (Lond) 9(8):1209-22, 2014. e-Pub 2014. PMID: 24063415.
- Xu, Y, Fattah, EA, Liu, X, Jagannath, C, Eissa, NT. Harnessing of TLR-mediated autophagy to combat mycobacteria in macrophages. Tuberculosis 93(SUPPL):S33-S37, 2013. e-Pub 2013. PMID: 24388647.
- Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, Yu-Lee LY. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 32(24):2973-83, 2013. e-Pub 2013. PMID: 22890325.
- Xu Y, Fattaha EA, Liu XD, Jagannath C, Eissaa NT. Harnessing of TLR-mediated autophagy to combat mycobacteria in macrophages. Tuberculosis:S33-S37, 2013. e-Pub 2013.
- Liu XD, Ko S, Xu Y, Fattah EA, Xiang Q, Jagannath C, Ishii T, Komatsu M, Eissa NT. Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 287(23):19687-98, 2012. e-Pub 2012. PMID: 22518844.
- Liu XD, Mazumdar T, Xu Y, Getzoff ED, Eissa NT. Identification of a flavin mononucleotide module residue critical for activity of inducible nitrite oxide synthase. J Immunol 183(9):5977-82, 2009. e-Pub 2009. PMID: 19828635.
- Xu Y, Liu XD, Gong X, Eissa NT. Signaling pathway of autophagy associated with innate immunity. Autophagy 4(1):110-2, 2008. e-Pub 2008. PMID: 18059159.
- Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27(1):135-44, 2007. e-Pub 2007. PMID: 17658277.
- Liu, X, Shen, YG. Salt shock induces state II transition of the photosynthetic apparatus in dark-adapted Dunaliella salina cells. Environmental and Experimental Botany 57(1-2):19-24, 2006. e-Pub 2006.
- Liu X, Shen Y. Salt shock induces state II transition of the photosynthetic apparatus in dark-adapted Dunaliella salina cells. Environmental and Experimental Botany 57(1–2):19-24, 2006. e-Pub 2006.
- Liu XD, Hu FH, Shen YG. Transient decrease of light-harvesting complex II phosphorylation level by hypoosmotic shock in dark-adapted Dunaliella salina. Acta Biochim Biophys Sin (Shanghai) 38(2):104-9, 2006. e-Pub 2006. PMID: 16474901.
- Liu XD, Shen YG. Changes in trans-thylakoid membrane proton motive force induced by treatments with red and far-red light in Dunaliella salina. Zhi Wu Sheng Li Yu Fen Zi Sheng Wu Xue Xue Bao 31(3):317-21, 2005. e-Pub 2005. PMID: 15961908.
- Liu XD, Shen YG. Salt-induced redox-independent phosphorylation of light harvesting chlorophyll a/b proteins in Dunaliella salina thylakoid membranes. Biochim Biophys Acta 1706(3):215-9, 2005. e-Pub 2005. PMID: 15694349.
- Liu XD, Shen YG. NaCl-induced phosphorylation of light harvesting chlorophyll a/b proteins in thylakoid membranes from the halotolerant green alga, Dunaliella salina. FEBS Lett 569(1-3):337-40, 2004. e-Pub 2004. PMID: 15225658.
- Liu, X, Shen, Y. Hypoosmotic shock induces a state I transition of photosynthetic apparatus in Dunaliella salina. Chinese Science Bulletin 49(7):672-675, 2004. e-Pub 2004.
- Liu X, Shen Y. Hypoosmotic shock induces a stateⅠtransition of photosynthetic apparatus in Dunaliella salina. Chinese Science Bulletin Vol. 49(No. 7):672—675, 2004. e-Pub 2004.
Invited Articles
- He H, Liu XD, Jonasch E. Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC. Frontiers of Medicine, 2025.
- Liu XD, Zhu H, DePavia A, Jonasch E. Dysregulation of HIF2a and autophagy in renal cell carcinoma. Molecular & Cellular Oncology 2(2):e965643, 2014. e-Pub 2014.
Review Articles
- He H, Liu XD, Jonasch E. Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC. MedScience 20(2):231-246, 2026. e-Pub 2026. PMID: 42189393.
- DePavia A, Jonasch E, Liu XD. Autophagy degrades hypoxia inducible factors. Mol Cell Oncol 3(2):e1104428, 2016. e-Pub 2016. PMID: 27308629.
- Liu XD, Ma WM, Shen YG. State transition of the photosynthetic apparatus in plant. Zhi Wu Sheng Li Yu Fen Zi Sheng Wu Xue Xue Bao 32(2):127-32, 2006. e-Pub 2006. PMID: 16622310.
Other Articles
- Gurumurthy CB, O'Brien AR, Quadros RM, Adams J, Alcaide P, Ayabe S, Ballard J, Batra SK, Beauchamp MC, Becker KA, Bernas G, Brough D, Carrillo-Salinas F, Chan W, Chen H, Dawson R, DeMambro V, D'Hont J, Dibb K, Eudy JD, Gan L, Gao J, Gonzales A, Guntur A, Guo H, Harms DW, Harrington A, Hentges KE, Humphreys N, Imai S, Ishii H, Iwama M, Jonasch E, Karolak M, Keavney B, Khin NC, Konno M, Kotani Y, Kunihiro Y, Lakshmanan I, Larochelle C, Lawrence CB, Li L, Lindner V, Liu XD, Lopez-Castejon G, Loudon A, Lowe J, Jerome-Majeweska L, Matsusaka T, Miura H, Miyasaka Y, Morpurgo B, Motyl K, Nabeshima YI, Nakade K, Nakashiba T, Nakashima K, Obata Y, Ogiwara S, Ouellet M, Oxburgh L, Piltz S, Pinz I, Ponnusamy MP, Ray D, Redder RJ, Rosen CJ, Ross N, Ruhe MT, Ryzhova L, Salvador AM, Alam SS, Sedlacek R, Sharma K, Smith C, Staes K, Starrs L, Sugiyama F, Takahashi S, Tanaka T, Trafford A, Uno Y, Vanhoutte L, Vanrockeghem F, Willis BJ, Wright CS, Yamauchi Y, Yi X, Yoshimi K, Zhang X, Zhang Y, Ohtsuka M, Das S, Garry DJ, Hochepied T, Thomas P, Parker-Thornburg J, Adamson AD, Yoshiki A, Schmouth JF, Golovko A, Thompson WR, Lloyd KCK, Wood JA, Cowan M, Mashimo T, Mizuno S, Zhu H, Kasparek P, Liaw L, Miano JM, Burgio G Response to correspondence on "Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation". Genome Biol 22(1):99, 2021. PMID: 33827648.
- Sung, YJ, Li, Y, Wang, Y, Chen, Y, Liu, X, Eissa, NT, Zhao, Y, Qin, J Complications in the assignment of 14 and 28 da mass shift detected by mass spectrometry as in vivo methylation from endogenous proteins (Analytical Chemistry (2008) 80, (1721-1729)). Analytical Chemistry 80(21):8353, 2008.
Abstracts
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma. 34th SITC Annual Meeting, 2019. e-Pub 2019.
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss reduces IFNg-STAT1 activity and promotes resistance to immunotherapy in renal cell carcinoma. Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, 2019. e-Pub 2019.
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss reduced IFNg-STAT1 activity and promotes resistance to immunotherapy in renal cell carcinoma. AACR Annual Meeting, 2019. e-Pub 2019.
- Liu XD, Zhu H, DePavia A, Sun M, Zhou L, Ding Z, Zhang X, Bai S, Walker C, Jonasch E. Macroautophagy and chaperone-mediated autophagy degrade immune checkpoint ligand PD-L1. Autophagy: Molecular and Physiological Mechanisms, 2016. e-Pub 2016.
- Liu XD, Hoang A, Sun M, Zhou L, Ding Z, Zhang X, Bai S, Tannir N, Jonasch E. Sunitinib upregulates IFNg-STAT1 signaling to modulate the tumor immune microenvironment in renal cell carcinoma. The Inaugural International Cancer Immunotherapy Conference, 2015. e-Pub 2015.
- Sun M, Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao, P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Angiogenic treatment both positively and negatively regulate the tumor immune microenvironment in metastatic renal cell carcinoma. Angiogenic treatment both positively and negatively regulate the tumor immune microenvironment in metastatic renal cell carcinoma, 2015. e-Pub 2015.
- Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Bai S, German P, Zhang X, Tamboli P, Rao P, Karam J, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Tannir N, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. ASCO Genitourinary Cancers Symposium, 2015. e-Pub 2015.
- Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. 2015 Genitourinary Cancers Symposium, 2015. e-Pub 2015.
- Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Bai S, German P, Zhang X, Tamboli P, Rao P, Karam J, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Tannir N, Sircar K, Jonasch E. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. 26th EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, 2014. e-Pub 2014.
- Liu XD, Hoang A, Zhou L, Kalra S, Sun M, Ding Z, Bai S, German P, Zhang X, Tamboli P, Rao P, Karam J, Wood C, Matin S, Tannir N, Sircar K, Jonasch E. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. ESMO 2014 Congress, 2014. e-Pub 2014.
- Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Zhang X, Conti CJ, Efstathiou E, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2 degradation and suppresses renal tumorigenesis. Keystone symposia, Autophagy: Fundamentals to disease, Selected Oral Presentation, 2014. e-Pub 2014.
- Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Zhang X, Conti CJ, Efstathiou E, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. American Association for Cancer Research (AACR) Annual Meeting, 2014. e-Pub 2014.
- Liu XD, Hoang A, Zhou L, Kalra S, Sun M, Ding Z, Bai S, German P, Zhang X, Tannir N, Sircar K, Jonasch E. Induced CD4 positive T-lymphocyte infiltration predicts poor survival in metastatic renal carcinoma patients treated with antiangiogenic therapy. The 5th international Meeting on Angiogenesis, 2014. e-Pub 2014.
- Xu Y, Liu X, Eissa T. Harnessing Of TLR-mediated Autophagy To Eliminate Mycobacterium Tuberculosis From Macrophages. American Thoracic Society, 2010. e-Pub 2010.
- Liu XD, Xu Y, Fung C, Dalu Z, Xiang Q, Jagannath C, Eissa NT. BCG Infection Induces P62-Dependent Autophagy-Independent Formation Of Dendritic Cell Aggresome-Like Structures. Am J Respir Crit Care Med. e-Pub 2010.
- Liu XD, Ko S, Xiang Q, Eissa TN. Alis Formation Is A Cytosolic Unfolded Protein Response To Inflammation And Endoplasmic Reticulum Stress. Am J Respir Crit Care Med. e-Pub 2010.
Patient Reviews
CV information above last modified September 04, 2026